Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. (Q51320301)

From Wikidata

Jump to navigation Jump to search

scientific article published on 24 June 2014

Language	Label	Description	Also known as
English	Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.	scientific article published on 24 June 2014

Statements

scholarly article

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial. (English)

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

phase II clinical trial

0 references

type 2 diabetes

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

3

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

author name string

Takashi Kadowaki

1

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Masakazu Haneda

2

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Yasuo Terauchi

4

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Atsushi Taniguchi

5

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Kazuki Koiwai

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Henning Rattunde

7

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Hans J Woerle

8

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Uli C Broedl

9

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

language of work or name

0 references

publication date

24 June 2014

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Advances in Therapy

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

31

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

621-638

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

6

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

https://scigraph.springernature.com/pub.10.1007/s12325-014-0126-8

0 references

Diabetes in Japan: a review of disease burden and approaches to treatment

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Global estimates of the prevalence of diabetes for 2010 and 2030

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Diabetes trends in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

The status of diabetes control and antidiabetic drug therapy in Japan--a cross-sectional survey of 17,000 patients with diabetes mellitus (JDDM 1).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Role of the kidney in normal glucose homeostasis and in the hyperglycaemia of diabetes mellitus: therapeutic implications

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin (BI 10773), a Potent and Selective SGLT2 Inhibitor, Induces Dose-Dependent Glucosuria in Healthy Subjects

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Pharmacokinetics, pharmacodynamics, safety and tolerability of 4 weeks' treatment with empagliflozin in Japanese patients with type 2 diabetes mellitus

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Long-term safety and efficacy of empagliflozin, sitagliptin, and metformin: an active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin as add-on to metformin plus sulfonylurea in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Revised equations for estimated GFR from serum creatinine in Japan

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Incidence and progression of diabetic retinopathy in Japanese adults with type 2 diabetes: 8 year follow-up study of the Japan Diabetes Complications Study (JDCS).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Waist circumference as a cardiovascular and metabolic risk in Japanese patients with type 2 diabetes.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Components of metabolic syndrome and their combinations as predictors of cardiovascular disease in Japanese patients with type 2 diabetes. Implications for improved definition. Analysis from Japan Diabetes Complications Study (JDCS).

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.

1 reference

https://api.crossref.org/works/10.1007%2FS12325-014-0126-8

21 January 2018

Identifiers

10.1007/S12325-014-0126-8

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

1 reference

Europe PubMed Central

3 April 2018

http://europepmc.org/abstract/MED/24958326

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q51320301&oldid=1698362692"